Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

---

Transfection Reagent for Keratinocyte Cells (Keratinocytes)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Kit includes Transfection Enhancer reagent and recommended transfection protocol
• High transfection efficacy in the presence of serum
• Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro Keratinocyte transfection protocol: [PDF]
• Download Keratinocyte CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for Keratinocyte cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems Keratinocyte Transfection Protocol: [PDF]

Download MSDS: [PDF]

Keratinocyte Cell Line:

Keratinocytes are the most prevalent type of skin cells, comprising nearly 95% of the epidermis. Keratinocyte cells originate in the basal skin layer and grow densely outward through the layers of the epidermis. Keratinocyte cells are continuously shed and replaced from the outer layer. They are considered the building blocks of skin because they are responsible for keratin production, the key component of hair and nails. Keratinocyte cells are tightly interwoven and form seams between the nerves and underlying tissues of the epidermis. This allows them to create a protective barrier to prevent infectious substances coming into the body through the skin. Also, keratinocytes play an essential role in wound healing, demonstrating a higher expression of PDGF A (fibroblast stimulating platelet-derived growth factor) than fibroblasts and regulating fibroblast activity.

Keratinocytes are used to develop in vitro techniques to assess skin irritants. The cells are also the principal source of the proinflammatory cytokine IL-1 in the epidermis.  Studies have found that Bcl-2 overexpression protects keratinocytes from Ukrain-induced apoptosis. Keratinocytes are sometimes divided into smaller cell types, such as basal keratinocytes, which are located near the basal layer. There are multiple biomedical research applications using keratinocytes. Altogen Biosystems offers advanced cationic lipid-based Keratinocyte transfection reagent kits that can efficiently aid biomedical research related to keratinocytes. These kits can be utilized for the development of stable Keratinocyte cell lines and yield high transfection efficiency, as detected by qRT-PCR.

Data:

Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).

Figure 2. Protein expression of Cyclophilin B in Keratinocyte cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into Keratinocyte cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

• Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
• Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
• Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
• Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
• RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
• Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
• British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
• Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
• Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
• PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
• J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
• PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:
Altogen Biosystems transfection and electroporation products for life sciences and cancer research. Transfection reagents are developed for individual cancer cell line and transfection protocols are optimized for maximum delivery efficiency. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in  vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #1783)
• 1.5 ml (Catalog #1784)
• 1.5 ml CRISPR (Catalog #2164)
• 8.0 ml (Catalog #7053)

Altogen Biosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。 Altogen Biosystems全国代理部分产品列表： 货号 产品 规格 价格（美元） 5030       1703 A204 Transfection Reagent (Rhabdomyosarcoma) 0.5ml 170 1704 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml 348 窗体顶端 窗体底端   2101 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml CRISPR 548 窗体顶端 窗体底端   7018 A204 Transfection Reagent (Rhabdomyosarcoma) 8.0ml 1044 窗体顶端 窗体底端   1167 A375 Cells Transfection Reagent (CRL-1619) 0.5ml 195 1168 A375 Cells Transfection Reagent (CRL-1620) 1.5ml 427 2102 A375 Cells Transfection Reagent (CRL-1621) 1.5ml CRISPR 627 1169 A375 Cells Transfection Reagent (CRL-1622) 8.0ml 1281 5030 Nanoparticle In Vivo Transfection Reagent 0.5 ml - 10 injections  445 5010 LIPID In Vivo Transfection Reagent 0.5 ml - 10 injections 405 5040 PEG-Liposome In Vivo Transfection Reagent 0.5 ml - 10 injections 465 5020 POLYMER In Vivo Transfection Reagent 0.5 ml - 10 injections 425 5050 Pancreas In Vivo Transfection Kit 0.5 ml - 10 injections  495 5060 Liver In Vivo Transfection Kit 0.5 ml - 10 injections  495 5070 Kidney In Vivo Transfection Kit 0.5 ml - 10 injections  495 1721 BMS2 Transfection Reagent (Bone Marrow Cells) 0.5 ml  231 6345 C6 Transfection Reagent (Glioma Cells, CCL-107) 0.5 ml  199 6803 DLD-1 Transfection Reagent (Colon Cancer, CCL-221) 0.5 ml  201 1775 HUH-7 Transfection Reagent (Liver Cancer Cells) 0.5 ml  179